Maze Therapeutics, Inc.
MAZE
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.5B
Close$
$3.86
87.6% downside
Current Fair Value
87.6% downsideOvervalued by 87.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.50 Billion |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.05 |
| Beta | 2.15 |
| Outstanding Shares | 58,995,934 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -9.89 |
|---|---|
| PEG | -30.16 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.72
Average shareholder expectationRevenue Estimate
$2.86 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.76
Average shareholder expectationRevenue Estimate
$333,333
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 96.19% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.10%▼ 99.56% |
|---|---|
| Total Invested | $1.62M▼ 99.91% |
| Investors Holding | 11▼ 158.00% |
ESG Score
No data
About Maze Therapeutics, Inc.
141 employees
CEO: Jason Coloma Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small mol...